نتایج جستجو برای: جهش jak2
تعداد نتایج: 7772 فیلتر نتایج به سال:
Background: Sulfur mustard was the most widely applied chemical warfare agent by the Iraqi army in Iran–Iraq war (1983-1988). Considering the role of sulfur mustard toxicity in hematopoietic neoplasms and also new role of JAK2 mutation in these neoplasms, we assessed this mutation and delayed hematologic complications in veterans exposed to sulfur mustard. Methods: This case control st...
چکیده سابقه و هدف تغییر بیان میکرو RNA می‌تواند باعث شروع و پیشرفت سرطان شود. هدف از مطالعه حاضر، بررسی میزان بیان miR-125a و ارتباط آن با JAK2 allele burden و یافته‌های آزمایشگاهی در بیماران مبتلا به نئوپلاسم‌های میلوپرولیفراتیو شامل پلی‌سیتمی ورا (PV) و ترومبوسیتمی اساسی(ET) بود. مواد و روش‌ها مطالعه حاضر از نوع تجربی بود. در مجموع 40 بیمار مبتلا به PV و ET در زمان تشخیص مورد بررسی قرار گرف...
چکیده سابقه و هدف تغییر بیان میکرو rna می تواند باعث شروع و پیشرفت سرطان شود. هدف از مطالعه حاضر، بررسی میزان بیان mir-125a و ارتباط آن با jak2 allele burden و یافته های آزمایشگاهی در بیماران مبتلا به نئوپلاسم های میلوپرولیفراتیو شامل پلی سیتمی ورا (pv) و ترومبوسیتمی اساسی(et) بود. مواد و روش ها مطالعه حاضر از نوع تجربی بود. در مجموع 40 بیمار مبتلا به pv و et در زمان تشخیص مورد بررسی قرار گرفت...
The cytoplasmic tyrosine kinase Jak2 plays a crucial role in cytokine receptor signaling in hematopoietic cells. The activated Jak2-V617F mutant is present in most cases of BCR/ABL-negative myeloproliferative neoplasms and constitutively activates downstream signals from homodimeric cytokine receptors, such as the erythropoietin receptor (EpoR). Here we examine the effects of DNA damage stress ...
Fusions of the tyrosine kinase domain of JAK2 with multiple partners occur in leukemia/lymphoma where they reportedly promote JAK2-oligomerization and autonomous signalling, Affected entities are promising candidates for therapy with JAK2 signalling inhibitors. While JAK2-translocations occur in myeloid, B-cell and T-cell lymphoid neoplasms, our findings suggest their incidence among the last g...
The binding of angiotensin II (Ang II) to AT1 is known to increase the kinase activity of several nonreceptor tyrosine kinases including Jak2 and c-Src. In the present study, we demonstrate that treatment of vascular smooth muscle cells with Ang II results in a rapid and transient association of Jak2 and c-Src. This association is dependent on a catalytically active Jak2 kinase, because it is b...
BACKGROUND The non-receptor tyrosine kinase JAK2 is implicated in a group of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. JAK2-selective inhibitors are currently being evaluated in clinical trials. Data from drug-resistant chronic myeloid leukemia patients demonstrate that treatment with a small-molecule inhibitor generates resi...
The constitutively active JAK2 V617F mutant is the major determinant of human myeloproliferative neoplasms (MPNs). We show that coexpression of murine JAK2 V617F and the murine thrombopoietin (Tpo) receptor (TpoR, c-MPL) in hematopoietic cell lines or heterozygous knock-in of JAK2 V617F in mice leads to down-modulation of TpoR levels. Enhanced TpoR ubiquitinylation, proteasomal degradation, red...
The genetics of classical Hodgkin lymphoma (cHL) is poorly understood. The finding of a JAK2-involving t(4;9)(q21;p24) in 1 case of cHL prompted us to characterize this translocation on a molecular level and to determine the prevalence of JAK2 rearrangements in cHL. We showed that the t(4;9)(q21;p24) leads to a novel SEC31A-JAK2 fusion. Screening of 131 cHL cases identified 1 additional case wi...
Janus kinase 2 (JAK2) and calreticulin (CALR) constitute the two most frequent mutations in essential thrombocythemia (ET), and both are reported to be mutually exclusive. Hence, we examined a cohort of 123 myeloproliferative neoplasm (MPN) patients without BCR-ABL1 rearrangement and additional ET patients (n=96) for coexistence of JAK2 and CALR mutations. The frequency of CALR mutations was 20...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید